Home›Emtricitabine/Tdf

Emtricitabine/Tdf

Also known as: Truvada

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase InhibitorNucleoside Reverse Transcriptase Inhibitors

Route: Oral

Check Emtricitabine/Tdf Interactions →

19 interactions on record⛔ Black Box Warning

Emtricitabine/Tdf has 19 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Didanosine, Acyclovir, Adefovir Dipivoxil. Patients taking Emtricitabine/Tdf should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 19
Major: 1
Moderate: 16

Major (1)

Emtricitabine/Tdf + Didanosine— Coadministration increases didanosine concentrations and may potentiate didanosine-associated adverse reactions includin…

Moderate (16)

Emtricitabine/Tdf + Acyclovir— Coadministration may increase concentrations of FTC, tenofovir, and/or acyclovir due to competition for active tubular s…
Emtricitabine/Tdf + Adefovir Dipivoxil— Coadministration may increase concentrations of FTC, tenofovir, and/or adefovir dipivoxil due to competition for active …
Emtricitabine/Tdf + Atazanavir— HIV-1 Protease Inhibitors: atazanavirc lopinavir/ritonavirc atazanavir/ritonavirc darunavir/ritonavirc ↓ atazanavir ↑ te…
Emtricitabine/Tdf + Cidofovir— Coadministration may increase concentrations of FTC, tenofovir, and/or cidofovir due to competition for active tubular s…
Emtricitabine/Tdf + Darunavir— HIV-1 Protease Inhibitors: atazanavirc lopinavir/ritonavirc atazanavir/ritonavirc darunavir/ritonavirc ↓ atazanavir ↑ te…
Emtricitabine/Tdf + Ganciclovir— Coadministration may increase concentrations of FTC, tenofovir, and/or ganciclovir due to competition for active tubular…
Emtricitabine/Tdf + Gentamicin— Coadministration may increase concentrations of FTC, tenofovir, and/or gentamicin due to competition for active tubular …
Emtricitabine/Tdf + Ledipasvir— Hepatitis C Antiviral Agents: sofosbuvir/velpatasvirc sofosbuvir/velpatasvir/voxilaprevirc ledipasvir/sofosbuvirc ↑ teno…
Emtricitabine/Tdf + Lopinavir— HIV-1 Protease Inhibitors: atazanavirc lopinavir/ritonavirc atazanavir/ritonavirc darunavir/ritonavirc ↓ atazanavir ↑ te…
Emtricitabine/Tdf + Lopinavir And Ritonavir— Coadministration may alter lopinavir/ritonavir and tenofovir concentrations. Monitoring recommended.
Emtricitabine/Tdf + Ritonavir— HIV-1 Protease Inhibitors: atazanavirc lopinavir/ritonavirc atazanavir/ritonavirc darunavir/ritonavirc ↓ atazanavir ↑ te…
Emtricitabine/Tdf + Sofosbuvir— Hepatitis C Antiviral Agents: sofosbuvir/velpatasvirc sofosbuvir/velpatasvir/voxilaprevirc ledipasvir/sofosbuvirc ↑ teno…
Emtricitabine/Tdf + Valacyclovir— Coadministration may increase concentrations of FTC, tenofovir, and/or valacyclovir due to competition for active tubula…
Emtricitabine/Tdf + Valganciclovir— Coadministration may increase concentrations of FTC, tenofovir, and/or valganciclovir due to competition for active tubu…
Emtricitabine/Tdf + Velpatasvir— Hepatitis C Antiviral Agents: sofosbuvir/velpatasvirc sofosbuvir/velpatasvir/voxilaprevirc ledipasvir/sofosbuvirc ↑ teno…
Emtricitabine/Tdf + Voxilaprevir— Hepatitis C Antiviral Agents: sofosbuvir/velpatasvirc sofosbuvir/velpatasvir/voxilaprevirc ledipasvir/sofosbuvirc ↑ teno…

Emtricitabine/Tdf + Didanosine⚠️Major

Coadministration increases didanosine concentrations and may potentiate didanosine-associated adverse reactions including pancreatitis and neuropathy. Dose adjustment recommended.

Emtricitabine/Tdf + Acyclovir🟡Moderate

Coadministration may increase concentrations of FTC, tenofovir, and/or acyclovir due to competition for active tubular secretion in kidneys.

Emtricitabine/Tdf + Adefovir Dipivoxil🟡Moderate

Coadministration may increase concentrations of FTC, tenofovir, and/or adefovir dipivoxil due to competition for active tubular secretion in kidneys.

Emtricitabine/Tdf + Atazanavir🟡Moderate

Emtricitabine/Tdf + Cidofovir🟡Moderate

Coadministration may increase concentrations of FTC, tenofovir, and/or cidofovir due to competition for active tubular secretion in kidneys.

Emtricitabine/Tdf + Darunavir🟡Moderate

Emtricitabine/Tdf + Ganciclovir🟡Moderate

Coadministration may increase concentrations of FTC, tenofovir, and/or ganciclovir due to competition for active tubular secretion in kidneys.

Emtricitabine/Tdf + Gentamicin🟡Moderate

Coadministration may increase concentrations of FTC, tenofovir, and/or gentamicin due to competition for active tubular secretion in kidneys.

Emtricitabine/Tdf + Ledipasvir🟡Moderate

Hepatitis C Antiviral Agents: sofosbuvir/velpatasvirc sofosbuvir/velpatasvir/voxilaprevirc ledipasvir/sofosbuvirc ↑ tenofovir Monitor patients receiving emtricitabine and tenofovir disoproxil fumarate concomitantly with EPCLUSA® (sofosbuvir/velpatasvir) or VOSEVI® (sofosbuvir/velpatasvir/voxilaprevir) for adverse reactions associated with TDF. Monitor patients receiving emtricitabine and tenofovir disoproxil fumarate concomitantly with HARVONI® (ledipasvir/sofosbuvir) without an HIV-1 protease inhibitor/ritonavir or an HIV-1 protease inhibitor/cobicistat combination for adverse reactions associated with TDF.

Emtricitabine/Tdf + Lopinavir🟡Moderate

Emtricitabine/Tdf + Lopinavir And Ritonavir🟡Moderate

Coadministration may alter lopinavir/ritonavir and tenofovir concentrations. Monitoring recommended.

Emtricitabine/Tdf + Ritonavir🟡Moderate

HIV-1 Protease Inhibitors: atazanavirc lopinavir/ritonavirc atazanavir/ritonavirc darunavir/ritonavirc ↓ atazanavir ↑ tenofovir When coadministered with emtricitabine and tenofovir disoproxil fumarate, atazanavir 300 mg should be given with ritonavir 100 mg. Monitor patients receiving emtricitabine and tenofovir disoproxil fumarate concomitantly with lopinavir/ritonavir, ritonavir-boosted atazanavir, or ritonavir-boosted darunavir for TDF-associated adverse reactions. Monitor patients receiving emtricitabine and tenofovir disoproxil fumarate concomitantly with HARVONI® (ledipasvir/sofosbuvir) without an HIV-1 protease inhibitor/ritonavir or an HIV-1 protease inhibitor/cobicistat combination for adverse reactions associated with TDF.

Emtricitabine/Tdf + Sofosbuvir🟡Moderate

Emtricitabine/Tdf + Valacyclovir🟡Moderate

Coadministration may increase concentrations of FTC, tenofovir, and/or valacyclovir due to competition for active tubular secretion in kidneys.

Emtricitabine/Tdf + Valganciclovir🟡Moderate

Coadministration may increase concentrations of FTC, tenofovir, and/or valganciclovir due to competition for active tubular secretion in kidneys.

Emtricitabine/Tdf + Velpatasvir🟡Moderate

Emtricitabine/Tdf + Voxilaprevir🟡Moderate

Emtricitabine/Tdf + Adefovirℹ️Unknown

Some examples include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see WARNINGS AND PRECAUTIONS (5.3)].

Emtricitabine/Tdf + Tenofovirℹ️Unknown

7.1 Drugs Affecting Renal Function FTC and tenofovir are primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion [see CLINICAL PHARMACOLOGY (12.3)]. No drug-drug interactions due to competition for renal excretion have been observed; however, coadministration of emtricitabine and tenofovir disoproxil fumarate with drugs that are eliminated by active tubular secretion may increase concentrations of FTC, tenofovir, and/or the coadministered drug. Drugs that decrease renal function may increase concentrations of FTC and/or tenofovir.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.